Status: Recruiting
A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia
To evaluate the efficacy of asciminib adding on tyrosine-kinase inhibitors (TKI) to achieve treatment-free remission (TFR) in chronic myeloid leukemia (CML) patients in chronic phase who failed prior cessation study of TKI
Participants needed: 69
Trial details
Phase: Phase 2Age: 19+Biological sex: AllType: InterventionalSponsor: Korean Society of HematologyUpdated: Apr 2, 2026Locations: 1
Eligibility criteria
19 year or older [+9]
Patients who experienced grade 3 or higher adverse events with TKIs (imatinib, d... [+10]